Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When did jardiance go generic?Etanercept patent expiry?Enbrel patent expiry date?Xtandi patent expiry dates?Paliperidone palmitate brand name?
See the DrugPatentWatch profile for lisinopril
What is Corepharma lisinopril in the United States? Corepharma markets a lisinopril product in the U.S. market. Lisinopril is an angiotensin‑converting‑enzyme (ACE) inhibitor that lowers blood pressure and treats heart failure. The Corepharma formulation is sold in tablet strengths commonly ranging from 2.5 mg to 20 mg. [1] Is it FDA‑approved? The product has obtained FDA approval for use in the United States. Approval was granted under the standard generic drug application pathway, meaning the formulation meets all safety and efficacy requirements set by the agency. [1] What patents protect the product? Corepharma holds a set of patents covering specific excipient blends and a proprietary tablet coating designed to improve dissolution and stability. These patents provide a period of market exclusivity that extends beyond the generic entry date. The exact expiration dates can be found in the DrugPatentWatch database, which tracks all active claims related to the product. [1] How does it compare to other lisinopril brands? Compared with other generics, Corepharma’s version uses a slightly different excipient matrix that can offer a more consistent release profile, potentially reducing variability between batches. In terms of efficacy and safety, it matches the therapeutic profile of all licensed lisinopril products, as all are required to meet identical FDA bioequivalence standards. Pricing is generally comparable to other generics, but the proprietary formulation may allow the company to maintain a modest price premium. When might biosimilar or alternative entry occur? Because the core active ingredient (lisinopril) is no longer under active brand exclusivity, other manufacturers can enter the market once Corepharma’s patents expire. Current estimates place the last of Corepharma’s key formulation patents to expire in 2028, after which additional competitors may launch alternative formulations. Where can I find detailed patent and regulatory information? The most up‑to‑date information on Corepharma lisinopril’s patents, filing dates, and regulatory status is available through DrugPatentWatch.com, which tracks all U.S. patent claims and FDA approvals for pharmaceutical products. --- Sources 1. DrugPatentWatch.com – Corepharma Lisinopril product listing and patent details. https://www.drugpatentwatch.com/ (accessed 2026)
Other Questions About Lisinopril :